<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Viral infections following lung transplantation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Viral infections following lung transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Viral infections following lung transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael G Ison, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1664678081"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A wide range of viral infections complicate lung transplantation. This topic review will focus on community respiratory viruses (eg, influenza, respiratory syncytial virus, adenovirus, parainfluenza virus, human metapneumovirus, rhinovirus), herpes simplex virus, and varicella-zoster virus.</p><p>Cytomegalovirus infection in lung transplant recipients is covered in detail separately. Likewise, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is covered in detail separately. Bacterial, mycobacterial, and fungal infections in solid organ transplant recipients are also discussed in the following topics: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H384771"><span class="h1">COMMUNITY RESPIRATORY VIRUSES</span></p><p class="headingAnchor" id="H1754194717"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Among immunocompromised patients, community respiratory viruses (CRVs) have been best studied in hematopoietic cell transplant and lung transplant recipients. Historically, studies defining the epidemiology and clinical virology of CRVs in lung transplant recipients have been retrospective, have involved inpatients only, and have used culture-based diagnostic techniques in patients with severe respiratory symptoms. As a result, these studies may underestimate the incidence and overestimate the severity of CRVs in lung transplant recipients. A few more contemporary studies have used molecular techniques applied prospectively to all lung transplant recipients, including outpatients and asymptomatic individuals; these studies are summarized in the following table  (<a class="graphic graphic_table graphicRef59838" href="/d/graphic/59838.html" rel="external">table 1</a>) [<a href="#rid1">1-10</a>].</p><p>Our understanding of CRVs in lung transplant recipients has improved over time. Nonetheless, there are several significant gaps in our knowledge that warrant further investigation. Additional prospective studies carried out over several years and in different geographic regions are needed to best define the epidemiology and clinical impact of CRVs in lung transplant recipients. Such studies should include both healthy outpatients and those with clinical disease and should be correlated with clinical course and pulmonary function testing. These studies would ideally use a broad array of molecular diagnostic tests to identify the widest range of viruses. In patients with documented infection, serial monitoring using quantitative molecular testing should be performed to define the natural history of the CRVs in this population. In addition, studies of available and investigational antiviral agents are needed to define the optimal antiviral regimen, dosing, and duration of therapy as well as the impact of therapy on secondary infections and on the development of acute and/or chronic rejection.</p><p class="headingAnchor" id="H231754831"><span class="h2">Epidemiology and risk factors</span><span class="headingEndMark"> — </span>Because of the lung's exposure to the environment, inhaled viruses are of particular concern and can be divided into pathogens that primarily affect the respiratory tract (CRVs, such as influenza, respiratory syncytial virus [RSV], parainfluenza virus [PIV], adenovirus, human metapneumovirus [hMPV], rhinovirus, and coronaviruses) and pathogens that predominantly affect other tissues (eg, cytomegalovirus [CMV], varicella-zoster virus [VZV], herpes simplex virus [HSV], measles). Adenovirus can be either a primary respiratory pathogen or the lungs can be involved as part of a disseminated infection.</p><p>The incidence of disease with CRVs varies in individual patient populations, depending in part on the incidence of disease in different geographic regions. Children tend to have more CRV infections than adults. Lung transplant recipients with exposure to children, particularly in the household, are at greater risk of CRV infection. Risk factors for progression to lower respiratory tract disease or severe illness among lung transplant recipients include being a child, having received recent lymphodepletion or treatment for rejection, and having had early post-transplant infections [<a href="#rid11">11,12</a>].</p><p>The epidemiology of individual viral infections and the coronavirus disease 2019 (COVID-19) pandemic are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7006.html" rel="external">"Influenza: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/7009.html" rel="external">"Parainfluenza viruses in adults", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/5975.html" rel="external">"Parainfluenza viruses in children", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/8304.html" rel="external">"Epidemiology of varicella-zoster virus infection: Chickenpox"</a> and  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/142052.html" rel="external">"Respiratory syncytial virus infection in adults"</a>.)</p><p class="headingAnchor" id="H1754194724"><span class="h3">Seasonal patterns</span><span class="headingEndMark"> — </span>The seasonal patterns of the individual CRVs in lung transplant recipients are similar to those seen in immunocompetent hosts:</p><p class="bulletIndent1"><span class="glyph">●</span>Outbreaks of influenza generally occur during the winter months in the northern and southern hemispheres (which occur at different times of year). In the temperate northern hemisphere, influenza predominates from November through April with <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fabout%2Fseason%2Findex.html%23%3A%7E%3Atext%3DThe%2520exact%2520timing%2520and%2520duration%2Clast%2520as%2520late%2520as%2520Maythat&amp;token=pjvTpcSx2KTfZ9EIIsUgEsgJ5xRNzSopOb9XLCs3zBUq6hLg4r8AFa8NS%2BpJBhaQsIWs%2BJC7QjFAipVt0jj1uYR4UA0KAUCg27iEQxYO3Lcn6kVhOx4XgKQRsGc6W5HMqKZW7SqAVB8MmXHF4ILPog%3D%3D&amp;TOPIC_ID=13952" target="_blank">variable peaks</a> that typically occur in January or February. In tropical regions, influenza occurs throughout the year. (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RSV causes seasonal outbreaks throughout the world; the typical season of outbreak activity depends upon the geographic region. The pattern in the United States is summarized in the following figure  (<a class="graphic graphic_figure graphicRef56691" href="/d/graphic/56691.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>hMPV appears to cause infections with seasonal variation in different regions: late winter and early spring the United States and northern Europe, and late spring and summer in Asia. (See  <a class="medical medical_review" href="/d/html/8311.html" rel="external">"Human metapneumovirus infections", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PIV infections occur throughout the world and throughout the year, with certain serotypes predominating during the spring or fall  (<a class="graphic graphic_figure graphicRef56691" href="/d/graphic/56691.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/7009.html" rel="external">"Parainfluenza viruses in adults", section on 'Seasonality'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adenovirus has a worldwide distribution, and infections occur throughout the year. (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SARS-CoV-2 transmission dynamics are discussed separately. (See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Epidemiology'</a>.)</p><p></p><p class="headingAnchor" id="H1754194731"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>CRVs can cause both upper and lower respiratory tract infections in lung transplant recipients. There are no pathognomonic signs or symptoms associated with a single CRV, and there is almost always cocirculation of multiple viral pathogens [<a href="#rid13">13</a>]. It is therefore impossible to determine the etiology on clinical grounds alone, and respiratory samples must be tested to make a definitive virologic diagnosis, as discussed below. (See <a class="local">'Diagnosis'</a> below.)</p><p>Signs and symptoms associated with upper respiratory tract infections caused by CRVs are often muted in lung transplant recipients because the inflammatory response is impaired by immunosuppressive therapy. Most lung transplant recipients with viral upper respiratory tract infections present with respiratory complaints or objective changes in pulmonary function test (PFT) results compared with baseline values. Rarely, isolated changes in PFTs are the only sign of infection. (See  <a class="medical medical_review" href="/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient", section on 'General principles'</a>.)</p><p>Asymptomatic infections have been recognized with certain viruses, especially rhinovirus [<a href="#rid14">14-17</a>].</p><p class="headingAnchor" id="H231757032"><span class="h3">Lung imaging</span><span class="headingEndMark"> — </span>In patients with pneumonia caused by a CRV, high-resolution chest computed tomography (CT) may reveal interstitial infiltrates, ground-glass opacities, nodules  (<a class="graphic graphic_diagnosticimage graphicRef68781" href="/d/graphic/68781.html" rel="external">image 1</a>), tree-in-bud opacities, and/or airspace consolidations  (<a class="graphic graphic_diagnosticimage graphicRef69600" href="/d/graphic/69600.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef78287" href="/d/graphic/78287.html" rel="external">image 3</a>), which may be indistinguishable from findings noted with other viral and nonviral pathogens [<a href="#rid18">18</a>].</p><p>High-resolution CT of the lungs is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6988.html" rel="external">"High resolution computed tomography of the lungs"</a>.)</p><p class="headingAnchor" id="H3793771572"><span class="h2">Potential complications</span></p><p class="headingAnchor" id="H2741441193"><span class="h3">Secondary infections</span><span class="headingEndMark"> — </span>Lung transplant recipients are at increased risk of secondary infectious complications of CRV infections, such as bacterial and fungal pneumonias [<a href="#rid11">11,19</a>]. In a retrospective review of 132 lung transplant recipients at a single center, 15 percent developed an invasive fungal infection (mostly invasive aspergillosis) [<a href="#rid20">20</a>]. Secondary invasive fungal infections were associated with chronic lung allograft dysfunction (CLAD) progression and death. CRVs may cause local mucosal defects and changes in cell surface peptides, which in turn may predispose to colonization and local invasion of colonizing fungi and bacteria.</p><p class="headingAnchor" id="H2809662001"><span class="h3">Rejection</span><span class="headingEndMark"> — </span>Transplanted lungs are susceptible to several different types of rejection. These include acute cellular rejection, humoral rejection, and CLAD. There are two types of CLAD, bronchiolitis obliterans syndrome and restrictive allograft syndrome. (See  <a class="medical medical_review" href="/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Definition'</a>.)</p><p>CRVs, particularly when associated with lower respiratory tract involvement, may be associated with rejection, the most common type of which is CLAD, previously referred to as bronchiolitis obliterans syndrome [<a href="#rid8">8,12,21-34</a>]. While the link between CRVs and CLAD is strong, the link between CRVs and acute rejection is less clear; most later studies have not demonstrated a correlation. Lymphocytic infiltrates are the expected response to viral infections and likely the reason that rejection has been diagnosed in some patients with CRV infection.</p><p>CLAD has been associated with several CRVs, particularly when the virus involves the lower respiratory tract [<a href="#rid1">1,21-28,31,33,34</a>]. Lower respiratory tract CRV infection causes local mucosal damage, exposing the host to alloantigen. There is at least one animal model that has demonstrated a correlation between lower respiratory tract infection with Sendai virus, a virus related to PIV, and CLAD [<a href="#rid35">35</a>]. Viruses that more commonly replicate in the lower respiratory tract, including hMPV, influenza, PIV, and RSV are more strongly linked with development of CLAD. A study found an association between CLAD and coronavirus infections, although this finding needs confirmation by other groups [<a href="#rid36">36</a>].</p><p>In a retrospective study that included 250 lung transplant recipients, 50 (20 percent) were diagnosed with CLAD and 79 (32 percent) had 114 episodes of CRV infection; most CRV infections were lower respiratory tract infections (85 percent) [<a href="#rid31">31</a>]. On multivariate analysis, rejection (adjusted hazard ratio [aHR] 2.2, 95% CI 1.2-3.9) and CRV infection (aHR 1.9, 95% CI 1.1-3.5) were independently associated with CLAD. The association of CRV infection with CLAD was stronger the more proximate the CRV infection (aHRs 4.8, 3.4, and 2.4 for 3 months, 6 months, and 9 months following CRV infection, respectively).</p><p>In a separate study of 139 lung transplant recipients that prospectively monitored CRV infections, the risk of CLAD was increased among those with CRV pneumonia (HR 3.94, 95% CI 1.97-7.90) but not symptomatic CRV infection or asymptomatic CRV infection [<a href="#rid32">32</a>]. The risk of graft loss was not increased by asymptomatic or symptomatic CRV infection.</p><p>A systematic review of observational studies, which included 1060 of CLAD, reported low 30-day mortality (0 to 3 percent) in lung transplant recipients with RSV, hMPV, and PIV infection. However, the incidence of CLAD was 19 to 24 percent 180 to 365 days after infection with these viruses [<a href="#rid37">37</a>].</p><p>The association between CRVs and acute rejection has not been established, with studies showing conflicting results [<a href="#rid38">38</a>]. One reason that it has been difficult to evaluate this potential association is that the cellular infiltrates observed in patients with CRVs may represent the host's appropriate response to the viral infection rather than rejection [<a href="#rid39">39</a>]. Several prospective studies have failed to find an association between CRV infection and acute rejection [<a href="#rid17">17,39,40</a>]. On the other hand, one study reported a 33 percent acute rejection rate in patients who had had a CRV infection within the past three months compared with 7 percent of those who did not have a recent CRV infection [<a href="#rid8">8</a>]. A limitation of this study is that the patients considered to have acute rejection included not only those with grade ≥2 biopsy-proven acute rejection but also those with a ≥20 percent decline in forced expiratory volume in 1 second (FEV<sub>1</sub>), which could be caused by conditions other than acute rejection. No significant difference was seen in the incidence of acute rejection between symptomatic and asymptomatic patients.</p><p>Cytomegalovirus has also been associated with CLAD. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients", section on 'Indirect effects'</a>.)</p><p>Other viruses, such as human herpes virus 6 and Epstein-Barr virus, have been associated with an increased risk of bronchiolitis obliterans syndrome in some but not all studies [<a href="#rid41">41-43</a>].</p><p>Rejection in lung transplant recipients is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a> and  <a class="medical medical_review" href="/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection"</a> and  <a class="medical medical_review" href="/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"</a>.)</p><p class="headingAnchor" id="H1754194981"><span class="h2">Diagnosis</span></p><p class="headingAnchor" id="H231754927"><span class="h3">Approach to diagnosis</span><span class="headingEndMark"> — </span>CRVs should be tested for in any lung transplant recipient presenting with fever, respiratory symptoms, or changes in pulmonary function testing results. In lung transplant recipients with mild to moderate respiratory illness, we start by obtaining nasopharyngeal samples (swabs or washings) for CRV testing. Available tests and techniques vary by institution. Some institutions use individual tests for each CRV, whereas others use a multiplex polymerase chain reaction (PCR) to test for a panel of CRVs. The multiplex PCRs frequently include rhinovirus and coronaviruses, which are less clinically significant and may be shed for long periods of time after clinical recovery from infection. Further, these assays detect common coronaviruses associated with the common cold but not the rare, more lethal SARS, Middle East respiratory syndrome (MERS); most assays do detect SARS-CoV-2 and COVID-19 (see  <a class="medical medical_review" href="/d/html/3027.html" rel="external">"Severe acute respiratory syndrome (SARS)"</a> and  <a class="medical medical_review" href="/d/html/106589.html" rel="external">"Middle East respiratory syndrome coronavirus: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>). We typically test for COVID-19, influenza, PIV, RSV, adenovirus, and hMPV in lung transplant recipients presenting with a respiratory illness. We have a low threshold for repeating testing for certain CRVs (eg, influenza) if initial testing is negative but the virus is known to be circulating locally; this is particularly important if effective antiviral therapy is available. Likewise, if molecular testing is only performed for SARS-CoV-2, repeating testing for a wider range of viruses should be performed as cocirculation of multiple viruses does occur. </p><p>In patients who have evidence of pneumonia and who are severely ill and in whom the diagnosis has not been made by less invasive techniques, we generally favor bronchoscopy with bronchoalveolar lavage (BAL). Up to 20 percent of patients with pneumonia or lower tract disease may not have virus detected in upper airway samples. The following table lists various tests that can be performed on BAL fluid  (<a class="graphic graphic_table graphicRef70685" href="/d/graphic/70685.html" rel="external">table 2</a>). The decision of which studies to perform depends upon the individual patient's epidemiologic exposures and clinical findings and on availability at specific hospital laboratories. When the diagnosis is not established by studies of BAL fluid or noninvasive testing, histopathology of lung tissue can be helpful.</p><p>The diagnosis of specific CRVs and community-acquired pneumonia is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/8311.html" rel="external">"Human metapneumovirus infections", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/7009.html" rel="external">"Parainfluenza viruses in adults", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5975.html" rel="external">"Parainfluenza viruses in children", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p>The approach to the immunocompromised patient with fever and pulmonary infiltrates is also presented elsewhere. (See  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.)</p><p class="headingAnchor" id="H231754985"><span class="h3">Diagnostic tests</span><span class="headingEndMark"> — </span>Given how nonspecific the clinical findings of CRVs are, it is useful to test for a wide range of viruses. Molecular diagnostic techniques (eg, PCR) are preferred. Nearly every study in immunocompromised patients, including those focusing on lung transplant recipients, has demonstrated that PCR provides greater yield and sensitivity than culture or direct florescent antibody (DFA) [<a href="#rid2">2,5,6,12,21,44,45</a>]. Similarly, several PCR methods are quantitative or semiquantitative, which allows for serial monitoring of the clinical course and response to therapy.</p><p>Although rapid antigen detection systems have been developed for influenza, RSV, and adenovirus, their sensitivity is limited, particularly in immunocompromised adults [<a href="#rid11">11,46</a>]. SARS-CoV-2 rapid antigen testing is also available but has improved sensitivity. Nonetheless, negative rapid antigen results should therefore <strong>never</strong> be used to rule out the presence of disease. If rapid antigen testing is used, positive results should guide therapy, whereas negative results should mandate additional testing.</p><p>Culture is insensitive for some viruses (eg, PIV, rhinovirus, hMPV infections), and there are limited reagents to allow routine DFA testing for other viruses (eg, rhinovirus, coronavirus).</p><p>Some transplant centers routinely test for CRVs whenever a bronchoscopy is performed. However, the relevance of respiratory viruses detected from asymptomatic lung transplant recipients remains to be defined, particularly rhinovirus and seasonal coronaviruses.</p><p class="headingAnchor" id="H1931378"><span class="h3">Specimen type</span><span class="headingEndMark"> — </span>The optimal specimens for CRV testing are nasopharyngeal aspirates, washings, and swabs. Nasopharyngeal washings are generally more sensitive than nasopharyngeal swabs for the detection of CRVs [<a href="#rid47">47</a>], but nasopharyngeal swabs are easier to obtain. In hospitalized patients with suspected CRV infection, specimens can be collected from different respiratory sites and on more than one day to increase the likelihood of detection [<a href="#rid48">48</a>]. In particular, in mechanically ventilated patients, upper (nasopharyngeal aspirates, washings, and/or swabs) and lower (BAL fluid, endotracheal aspirates and/or washes) respiratory tract samples should be obtained if CRV infection is suspected but not yet confirmed [<a href="#rid49">49</a>].</p><p>A <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMe0903992&amp;token=qPRSykph7sfSN5jwrFloS0yqCfd5aJZXJsbZGboQoMUm52H917Ts9H4UHQHQtxcwFOW7xzGoGaiFvYLObq1u%2Bw%3D%3D&amp;TOPIC_ID=13952" target="_blank">video</a> reviews the proper technique for nasopharyngeal swab collection.</p><p>The optimal specimen type has been best studied for influenza infection. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H231757135"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Both the clinical and radiographic findings associated with CRVs are nonspecific. In lung transplant recipients presenting with signs and symptoms that are suggestive of a CRV infection (eg, fever, cough, shortness of breath, reduced pulmonary function testing results), a variety of viral and nonviral causes should be considered:</p><p class="bulletIndent1"><span class="glyph">●</span>Viral causes include the CRVs (influenza, RSV, PIV, hMPV) and other viruses (adenovirus, CMV, VZV, HSV, SARS-CoV-2). (See  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children"</a> and  <a class="medical medical_review" href="/d/html/7009.html" rel="external">"Parainfluenza viruses in adults"</a> and  <a class="medical medical_review" href="/d/html/5975.html" rel="external">"Parainfluenza viruses in children"</a> and  <a class="medical medical_review" href="/d/html/8311.html" rel="external">"Human metapneumovirus infections"</a> and  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection"</a> and  <a class="medical medical_review" href="/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/8284.html" rel="external">"Clinical features of varicella-zoster virus infection: Chickenpox", section on 'Pneumonia'</a> and  <a class="medical medical_review" href="/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Respiratory tract infections'</a> and  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians should have a high index of suspicion for CMV in patients who have recently discontinued CMV prophylaxis or who have recently been treated for rejection. (See  <a class="medical medical_review" href="/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other infections (bacterial, mycobacterial, fungal, parasitic) also cause pneumonia that can sometimes be difficult to distinguish from viral causes but often have distinguishing radiographic features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lobar consolidation is suggestive of bacterial (eg, pneumococcal) pneumonia. (See  <a class="medical medical_review" href="/d/html/6990.html" rel="external">"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atypical bacterial causes (eg, <em>Mycoplasma pneumoniae</em>, <em>Chlamydia pneumoniae</em>) may have a radiographic appearance that is similar to the appearance of viral pneumonia. (See  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6989.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in adults"</a> and  <a class="medical medical_review" href="/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children"</a> and  <a class="medical medical_review" href="/d/html/7036.html" rel="external">"Pneumonia caused by <i>Chlamydia pneumoniae</i> in adults"</a> and  <a class="medical medical_review" href="/d/html/5957.html" rel="external">"Pneumonia caused by <i>Chlamydia pneumoniae</i> in children"</a> and  <a class="medical medical_review" href="/d/html/7035.html" rel="external">"Clinical manifestations and diagnosis of <i>Legionella </i>infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nontuberculous mycobacteria can cause a range of lung imaging findings, including nodular or cavitary opacities and multiple small tree-in-bud opacities. (See  <a class="medical medical_review" href="/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis in lung transplant recipients can cause focal infiltrates, a miliary pattern, nodules, pleural effusions, diffuse interstitial infiltrates, and cavities. (See  <a class="medical medical_review" href="/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients", section on 'Radiographic findings'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fungal pathogens (eg, <em>Aspergillus</em> spp) typically cause nodules with surrounding ground-glass opacities. (See  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation", section on 'Pulmonary aspergillosis'</a> and  <a class="medical medical_review" href="/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute or chronic rejection can cause similar signs and symptoms as CRVs. The diagnosis of rejection is established by lung biopsy. (See <a class="local">'Rejection'</a> above and  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a> and  <a class="medical medical_review" href="/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection"</a> and  <a class="medical medical_review" href="/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"</a>.)</p><p></p><p>Pulmonary infections in immunocompromised patients are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1402.html" rel="external">"Epidemiology of pulmonary infections in immunocompromised patients"</a> and  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.)</p><p class="headingAnchor" id="H1754194738"><span class="h2">Viral shedding</span><span class="headingEndMark"> — </span>Prolonged shedding is typical of CRVs in lung transplant recipients [<a href="#rid30">30</a>]. This has been best demonstrated with rhinovirus, in which shedding has been documented for months [<a href="#rid21">21</a>]. Patients with prolonged shedding may benefit from longer durations of therapy, as discussed below. (See <a class="local">'Therapy'</a> below.)</p><p>Studies that evaluate the kinetics of viral shedding using quantitative assays are needed for most CRVs to elucidate the natural history of treated and untreated infection in lung transplant recipients. </p><p class="headingAnchor" id="H1754194759"><span class="h2">Management</span><span class="headingEndMark"> — </span>The management of CRVs varies with the specific virus causing the infection [<a href="#rid50">50</a>]. Effective antiviral agents are available for certain CRVs (eg, influenza) but not for others. Among the CRVs, a vaccine is available only for influenza virus.</p><p>An overview of the approach to management in lung transplant recipients is provided here. Management for each virus is discussed in greater detail in the disease-specific topic reviews.</p><p class="headingAnchor" id="H1664678088"><span class="h3">Influenza</span></p><p class="headingAnchor" id="H1664678105"><span class="h4">Therapy</span><span class="headingEndMark"> — </span>Since ongoing replication of influenza virus may be correlated with secondary infections and rejection, antiviral therapy should be given to <strong>all</strong> lung transplant recipients with influenza virus infection, irrespective of the severity of infection or the interval between onset of symptoms and diagnosis [<a href="#rid30">30,51</a>]. If influenza is strongly suspected, antiviral therapy should be started while awaiting test results [<a href="#rid30">30</a>].</p><p>The usual treatment is a neuraminidase inhibitor (eg, <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a>), but, because of the potential for resistance in circulating strains of influenza, the appropriate antiviral agent should be guided by the recommendations of local and national health agencies  (<a class="graphic graphic_table graphicRef50350" href="/d/graphic/50350.html" rel="external">table 3</a>) [<a href="#rid52">52</a>]. <a class="drug drug_general" data-topicid="119458" href="/d/drug information/119458.html" rel="external">Baloxavir</a>, a new influenza antiviral agent, has been approved for influenza treatment in healthy adults in the United States [<a href="#rid53">53</a>]. However, we do not use this agent for influenza treatment in immunocompromised patients, including lung transplant recipients, because it has not been studied in this population and because resistance can emerge during therapy [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p>We continue antiviral therapy in lung transplant recipients with influenza until shedding is no longer detected by real-time reverse-transcriptase PCR; this will typically require more than the five days of therapy recommended for immunocompetent individuals [<a href="#rid30">30</a>]. We typically start with 10 days of therapy and extend therapy if the patient remains PCR positive within a day of the planned stop date. The optimal duration of therapy has not been prospectively studied. If the patient continues with prolonged symptoms and signs with shedding or has clinical deterioration with ongoing replication, antiviral drug resistance should be considered. When there is clinical concern for resistance, appropriate testing should be performed and alternative therapy considered. (See  <a class="medical medical_review" href="/d/html/7008.html" rel="external">"Antiviral drugs for influenza: Pharmacology and resistance"</a>.)</p><p>The best evidence for the efficacy of antiviral therapy for influenza comes from randomized trials and meta-analyses of immunocompetent patients. In otherwise healthy immunocompetent adults and children, there is little benefit to the use of antivirals greater than 48 hours after symptom onset; this may not be the case with lung transplant recipients. Some studies have suggested that antiviral therapy reduces the severity and incidence of complications of influenza, the duration of hospitalization in patients with severe influenza, and influenza-associated mortality. (See  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p>There have been few prospective studies of the optimal timing, dose, or duration of antivirals in lung transplant recipients with influenza infection [<a href="#rid10">10,55-57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one prospective study, 228 immunocompromised patients (including transplant recipients) were randomized to receive standard-dose or double-dose <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a> [<a href="#rid57">57</a>]. Adverse event rates were lower (50.5 versus 59.1 percent) in patients receiving standard-dose therapy, but most of the difference was attributable to an increased rate of headaches. Resistant variants emerged on therapy more commonly with conventional-dose than double-dose therapy (12 versus 3 percent patients) and duration of shedding was shorter with double-dose therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of antiviral therapy in 237 solid organ transplant patients infected with 2009 pandemic influenza A/H1N1, 33 (14 percent) were lung transplant recipients [<a href="#rid55">55</a>]. Antiviral therapy (primarily <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a> monotherapy) was associated with improved outcomes, particularly if it was started early. Seven patients (8 percent) given antiviral drugs within 48 hours of symptom onset were admitted to an intensive care unit (ICU) compared with 28 (22 percent) given antivirals later.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of antiviral therapy in 616 solid organ transplant patients over a five-year period, including 116 transplant recipients, antiviral therapy (primarily <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a> monotherapy) was associated with improved outcomes, particularly when it was started early [<a href="#rid58">58</a>]. Influenza vaccination within the same influenza season was associated with reduced disease severity, pneumonia, and ICU admission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of nine lung transplant recipients, <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a> was associated with clinical and radiographic response and a reduced risk of bronchiolitis obliterans syndrome compared with historical controls [<a href="#rid56">56</a>]. Of note, most of the patients were previously vaccinated against influenza, and most had symptoms for ≥48 hours prior to starting antiviral therapy. Oseltamivir was generally well-tolerated and treatment interruptions were not reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series that included 10 lung transplant recipients with influenza, all patients tolerated <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a> and most did well despite prolonged shedding [<a href="#rid10">10</a>].</p><p></p><p>Several experimental antiviral agents are under investigation for influenza infection. (See  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment", section on 'Investigational approaches'</a>.)</p><p>Immunocompromised patients, including lung transplant recipients, are at greater risk for developing infection with drug-resistant influenza. Antiviral resistance should be suspected in patients who fail to improve clinically and have evidence of ongoing viral replication after 5 to 10 days of treatment (eg, patients with persistently reverse-transcriptase PCR). When resistance is suspected, resistance testing should be performed and antiviral therapy with two agents can be considered while awaiting results. (See  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis", section on 'Antiviral resistance'</a> and  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment", section on 'Patients with persistent symptoms'</a>.)</p><p>In addition, patients who fail to improve often have other causes or complications (eg, bacterial or fungal superinfection, rejection, acute respiratory distress syndrome), which should be evaluated. </p><p>The treatment of influenza infection is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p class="headingAnchor" id="H749194986"><span class="h4">Prevention</span><span class="headingEndMark"> — </span>Prevention of influenza depends on vaccination and, in some cases, on the use of antiviral prophylaxis.</p><p class="headingAnchor" id="H1112094335"><span class="h5">Vaccination</span><span class="headingEndMark"> — </span>Annual influenza vaccination is recommended for all lung transplant recipients (after the early post-transplant period) and their close contacts [<a href="#rid30">30,59</a>]. It is common to wait three to six months after transplantation before giving vaccines, once maintenance immunosuppression levels have been attained [<a href="#rid60">60</a>]. An exception is that during influenza outbreaks, it is reasonable to give the <a class="drug drug_general" data-topicid="9055" href="/d/drug information/9055.html" rel="external">inactivated influenza vaccine</a> as early as one month following transplantation [<a href="#rid61">61</a>]. It is strongly recommended that all close contacts of lung transplant recipients be vaccinated against influenza annually to provide a protective ring around the patient.</p><p>In lung transplant recipients, inactivated influenza vaccination has been shown to be safe without associated risk of rejection [<a href="#rid62">62-65</a>]; the live-attenuated intranasal vaccine is contraindicated in transplant patients because of the risk of infection by the vaccine strain. Although influenza vaccines are less immunogenic in lung transplant recipients when compared with immunocompetent individuals, they still appear to be effective [<a href="#rid66">66,67</a>]. The high-dose vaccine may augment immune response and does not appear to be associated with increased rates of rejection, though data are limited [<a href="#rid58">58,68,69</a>]. (See  <a class="medical medical_review" href="/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Influenza'</a>.)</p><p>Despite its safety and efficacy, influenza vaccination rates among lung transplant recipients and their close contacts remain poor. Interventions, such as letters sent to transplant recipients specifically recommending vaccination for both the recipient and his or her close contacts, should be considered to increase the uptake of vaccination in these patients.</p><p>Seasonal influenza vaccination is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Influenza'</a>.)</p><p class="headingAnchor" id="H50583913"><span class="h5">Antiviral prophylaxis</span><span class="headingEndMark"> — </span>We generally do not give pre-exposure prophylaxis to lung transplant recipients who are unlikely to have immunity out of concern that prolonged use of an antiviral agent could increase the risk of resistance. However, in the setting of significant influenza activity, we are most likely to give pre-exposure prophylaxis to those who underwent transplantation within the past month. The American Society of Transplantation states that, for lung transplant recipients in whom influenza vaccination is contraindicated or for those who are likely to have an inadequate response to the vaccine (eg, those receiving therapy for acute rejection or who underwent transplantation recently), pre-exposure antiviral prophylaxis for 12 weeks starting at the beginning of influenza season may be proposed  (<a class="graphic graphic_table graphicRef50350" href="/d/graphic/50350.html" rel="external">table 3</a>) [<a href="#rid30">30</a>].</p><p>In patients who meet criteria for pre-exposure prophylaxis described above but who are not receiving it and who have been exposed to a patient with influenza within the past 48 hours, the United States Advisory Committee on Immunization Practices recommends giving postexposure prophylaxis [<a href="#rid51">51</a>]. However, we prefer to either give such patients treatment dosing for five days or to closely observe such patients for signs and symptoms of infection and initiate treatment if they develop. We are most likely to offer treatment to exposed patients who underwent transplant within the past month. Our rationale for avoiding postexposure prophylaxis in most patients is that it might lead to the development of resistance. Postexposure prophylaxis and the development of antiviral resistance are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7017.html" rel="external">"Seasonal influenza in adults: Role of antiviral prophylaxis for prevention", section on 'Postexposure antiviral prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/7008.html" rel="external">"Antiviral drugs for influenza: Pharmacology and resistance"</a>.)</p><p>In a randomized trial, <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a> or placebo was given for 12 weeks during periods of local influenza circulation to kidney, liver, and hematopoietic cell transplant recipients [<a href="#rid70">70</a>]. Oseltamivir was well tolerated and was associated with a significant reduction in PCR-proven influenza infections compared with placebo (1.7 versus 8.4 percent). Although lung transplant recipients were not included in the trial, the results are likely to apply to this group.</p><p>Studies of neuraminidase inhibitors in immunocompetent patients have demonstrated protective efficacy when used for short-term prophylaxis. (See  <a class="medical medical_review" href="/d/html/7017.html" rel="external">"Seasonal influenza in adults: Role of antiviral prophylaxis for prevention"</a>.)</p><p class="headingAnchor" id="H833883307"><span class="h3">SARS-CoV-2</span><span class="headingEndMark"> — </span>The management of SARS-CoV-2 in lung transplant patients is generally similar to other patients with a few notable exceptions: </p><p class="bulletIndent1"><span class="glyph">●</span>The threshold to use approved and investigational therapies is lower but practice varies among transplant centers. Consideration of drug interactions and renal function should inform selection of agents. (See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'COVID-19-specific therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of vaccination is considerably lower. For messenger ribonucleic acid (mRNA) vaccines, additional doses are recommended as part of the primary series as well as booster dosing. (See  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Vaccination'</a>.)</p><p></p><p class="headingAnchor" id="H1664678113"><span class="h3">Respiratory syncytial virus</span><span class="headingEndMark"> — </span>RSV is a major cause of CRV infection in lung transplant recipients, particularly children [<a href="#rid71">71</a>]. Risk factors for severe RSV disease include age less than one year, acquisition of RSV infection during the early post-transplant period, and recent exposure to augmented immunosuppression [<a href="#rid72">72</a>].</p><p>Despite limited data, some centers give symptomatic patients with documented RSV pneumonia <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a>, which has in vitro activity against RSV. Oral ribavirin is most frequently used because of ease of use and lower cost compared with aerosolized ribavirin [<a href="#rid73">73-78</a>]. The author of this topic review agrees with this approach. However, it should be noted that some experts give supportive care only rather than antiviral therapy given the lack of clear evidence of benefit of antiviral therapy and the potential toxicity of ribavirin (most notably anemia). Oral ribavirin is typically dosed at 600 to 800 mg twice daily. Despite broad use of oral ribavirin in lung transplant recipients, clinical studies demonstrate drug levels in the lung during therapy are generally lower (8.3 mcg/mL) than when aerosolized (249 to 1379 mcg/mL); levels with oral therapy are well below the IC50 of ribavirin for RSV (17 to 30 mcg/mL) [<a href="#rid79">79</a>]. Duration is usually seven days or until clear improvement in symptoms.</p><p>There are limited observational data on the role of antiviral therapy in the management of RSV infection in lung transplant recipients. Traditionally, aerosolized <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> was advocated for the treatment of RSV infections, particularly pneumonia, but it is not clear that its use leads to improved outcomes [<a href="#rid71">71,80-85</a>]. Major drawbacks of aerosolized ribavirin include extremely high cost, intolerance, bronchospasm, and risk to the caretakers exposed to the therapy (because it is a teratogen) [<a href="#rid77">77</a>].</p><p>It is not clear whether glucocorticoids are beneficial for the management of RSV, but they are frequently used in combination with <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> by transplant clinicians because it is difficult to distinguish infection from rejection on biopsy and both may coexist. One study of five RSV-infected lung transplant recipients treated with glucocorticoids and oral ribavirin (15 to 20 mg/kg in three divided doses for a total of 10 days) concluded that the intervention was well-tolerated and less costly than aerosolized ribavirin [<a href="#rid77">77</a>]. No patients died.</p><p>There has also been interest in intravenous (IV) <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a>. However, it is not available. In one study, IV ribavirin plus oral <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> were given to 18 RSV-infected lung transplant recipients until repeat nasopharyngeal and throat swabs were negative for RSV on indirect fluorescent antibody testing in one retrospective study [<a href="#rid86">86</a>]. No patients died and all had a return to near baseline pulmonary function testing. Treatment was continued for a median of eight days and was well-tolerated except for mild hemolytic anemia in several patients.</p><p>There are some data suggesting improved outcomes for the treatment of RSV with aerosolized or oral <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> plus antibody-based therapy in hematopoietic cell transplant recipients [<a href="#rid87">87</a>]. However, there is insufficient evidence in lung transplant recipients to support the routine use of intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>), high RSV titer IVIG, or the monoclonal antibodies (eg, <a class="drug drug_general" data-topicid="9849" href="/d/drug information/9849.html" rel="external">palivizumab</a>). Such therapy may be considered in lung transplant recipients with severe pneumonia. However, because of the prohibitive cost of palivizumab in adults, when antibody therapy is desired, adults are typically treated with commercially available IVIG or by using the investigational high RSV titer IVIG product, RI-001 [<a href="#rid88">88</a>].</p><p>Several antivirals, including a novel small interfering RNA preparation, ALN-RSV01, and presatovir, a fusion inhibitor, have been studied for RSV but are no longer in clinical development [<a href="#rid89">89-91</a>]. Other agents are actively undergoing investigation, mostly in populations other than lung transplant patients.  </p><p>Prevention of RSV is evolving with the availability of novel monoclonal antibodies and vaccines.</p><p class="bulletIndent1"><span class="glyph">●</span>Two vaccines against RSV have been approved for use in adults ≥60 years old by the US Food and Drug Administration (FDA) [<a href="#rid92">92-94</a>]. While the studies that support the FDA approval did not include lung transplant recipients, we expect the benefit of vaccination to extend to transplant recipients and recommend their use in lung transplant recipients ≥60 years of age. Further efficacy data are needed to support use in younger transplant recipients. (See  <a class="medical medical_review" href="/d/html/97819.html" rel="external">"Overview of preventive care in adults", section on 'Immunization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="141488" href="/d/drug information/141488.html" rel="external">Nirsevimab</a> (a human recombinant monoclonal antibody that is active against RSV) has been studied for the prevention of RSV in infants [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/d/html/15389.html" rel="external">"Respiratory syncytial virus infection: Prevention in infants and children", section on 'Immunoprophylaxis'</a>.)</p><p></p><p class="bulletIndent1">Studies in immunocompromised infants are ongoing and studies in other immunocompromised populations are planned.</p><p></p><p class="headingAnchor" id="H1664678128"><span class="h3">Parainfluenza virus</span><span class="headingEndMark"> — </span>There are no antiviral agents that have been proven in prospective studies to be effective for treating PIV infections. The mainstay of therapy for PIV infection in immunocompromised hosts is reduction of immunosuppression, particularly reduction in the dose of glucocorticoids, when possible [<a href="#rid11">11</a>]. We do <strong>not</strong> use <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> for the treatment of PIV pneumonia given the lack of proven benefit.</p><p><a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">Ribavirin</a> has been used in a few isolated cases of severe PIV infection in lung transplant recipients with reportedly successful outcomes [<a href="#rid71">71,81</a>]. The possible benefit of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> has not been proven in humans [<a href="#rid96">96</a>]. DAS181, an investigational sialidase fusion inhibitor, has been studied in hematopoietic cell transplant patients, and the results of this trial are pending.</p><p>The treatment of PIV infections is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7009.html" rel="external">"Parainfluenza viruses in adults"</a> and  <a class="medical medical_review" href="/d/html/5975.html" rel="external">"Parainfluenza viruses in children", section on 'Treatment'</a>.)</p><p>There are no proven strategies other than infection control to prevent PIV in lung transplant patients. Hospitalized patients with PIV infection should be placed on standard and contact precautions and should have a private room whenever possible [<a href="#rid97">97</a>]. Respiratory precautions are not necessary because the droplets are large and do not aerosolize. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p class="headingAnchor" id="H749195239"><span class="h3">Adenovirus</span><span class="headingEndMark"> — </span>Adenovirus can cause pneumonia in lung transplant recipients [<a href="#rid98">98</a>]. As noted above, adenovirus can be either a primary respiratory pathogen or the lungs can be involved as part of a disseminated infection.</p><p><a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">Cidofovir</a> has been the antiviral agent most frequently used to treat adenovirus infections, but severe nephrotoxicity is a major dose-limiting toxicity. Cidofovir can also cause a Fanconi-type syndrome, with proteinuria, glucosuria, and bicarbonate wasting. <a class="drug drug_general" data-topicid="131802" href="/d/drug information/131802.html" rel="external">Brincidofovir</a>, a lipid ester of cidofovir, was studied for adenovirus [<a href="#rid99">99</a>]. Although the drug has been approved for the treatment of human smallpox, the label states that it cannot be used for other indications and is not available by compassion use [<a href="#rid99">99,100</a>]. An infectious diseases specialist should be consulted when treatment is being considered.</p><p>For lung transplant recipients with severe adenovirus pneumonia or disseminated disease, we generally give <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>. However, the decision of whether to give cidofovir should be made on a case-by-case basis, carefully weighing the potential risks and benefits. If cidofovir is given, it is usually dosed 5 mg/kg IV once together with <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a> and aggressive hydration. Renal function, urine protein, and electrolytes must be monitored closely. After the initial dose, repeated doses can be given at weekly intervals if the patient has not experienced significant toxicity and if it is deemed to be clinically necessary. There is experience with the use of 1 mg/kg three times a week in pediatric lung transplant patients where efficacy appears similar to higher dose but is associated with less renal toxicity; dosing with probenecid is also required with this approach [<a href="#rid101">101</a>]. Specific recommendations regarding the use of probenecid and hydration in patients receiving cidofovir are presented separately. The management of adenovirus infection is also discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/8297.html" rel="external">"Cidofovir: An overview", section on 'Toxicity'</a> and  <a class="medical medical_review" href="/d/html/8348.html" rel="external">"Diagnosis, treatment, and prevention of adenovirus infection"</a>.)</p><p>When using antivirals, the patient should be monitored with weekly quantitative viral load assessment of blood (if viremic) and respiratory specimens to guide decisions about the duration of therapy.</p><p class="headingAnchor" id="H749195269"><span class="h3">Human metapneumovirus</span><span class="headingEndMark"> — </span>We do <strong>not</strong> recommend antiviral therapy for the treatment of hMPV infections, as no studies have prospectively studied therapeutic interventions for hMPV in lung transplant recipients. <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">Ribavirin</a> has been used in a few cases of severe hMPV infection in lung transplant patients with successful outcomes reported [<a href="#rid102">102,103</a>]. (See  <a class="medical medical_review" href="/d/html/8311.html" rel="external">"Human metapneumovirus infections"</a>.)</p><p>There are no antiviral agents that have been proven effective for the prevention of hMPV infections.</p><p class="headingAnchor" id="H1664678137"><span class="h3">Other community respiratory viruses</span><span class="headingEndMark"> — </span>Data on other respiratory viruses in lung transplant recipients are limited [<a href="#rid9">9,21,104-107</a>]. Therapeutic interventions are either unproven or lacking. The respiratory polyomaviruses WU and KI have been associated with lower airway disease and symptoms in lung transplant recipients in some reports; confirmation of these findings may elucidate the clinical importance of this group of pathogens [<a href="#rid9">9,104,108</a>]. (See  <a class="medical medical_review" href="/d/html/8280.html" rel="external">"Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections", section on 'Classification'</a>.)</p><p>The role of rhinoviruses in lung transplant recipients has not been well studied, but it is likely that they can cause pneumonia in such patients. Prolonged shedding, even in the absence of symptoms, has been documented with rhinovirus infection [<a href="#rid21">21</a>]. The clinical significance of prolonged shedding warrants further study. (See  <a class="medical medical_review" href="/d/html/6990.html" rel="external">"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults", section on 'Rhinovirus'</a>.)</p><p>Coronaviruses have been documented in both upper and lower tract specimens and are typically the second or third most commonly detected viruses in lung transplant patients [<a href="#rid17">17,36,109</a>]. While most studies suggest that infected patients are symptomatic, only one study has associated coronavirus with chronic rejection (CLAD). SARS, MERS, and SARS-CoV-2 generally result in severe in transplant recipients, particularly lung transplant recipients [<a href="#rid110">110-112</a>]. When the lung transplant is performed for COVID-19-associated lung injury (ARDS or fibrosis), recipients have longer hospital stays, higher risk of early infections, but have similar one-year patient survival (COVID, 86.6 versus non-COVID, 86.3 percent). Post-transplant, COVID-19-associated deaths were 9.2 percent of all deaths among lung transplant recipients, highlighting ongoing risk of infection despite severe infection prior transplantation [<a href="#rid113">113</a>]. (See  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation"</a> and  <a class="medical medical_review" href="/d/html/3027.html" rel="external">"Severe acute respiratory syndrome (SARS)"</a> and  <a class="medical medical_review" href="/d/html/106550.html" rel="external">"Middle East respiratory syndrome coronavirus: Treatment and prevention"</a>.) </p><p class="headingAnchor" id="H1664678144"><span class="h2">Organ donation</span><span class="headingEndMark"> — </span>There are few prospective studies of donor-derived infections and, as a result, the true incidence of donor-derived respiratory virus transmission is unknown [<a href="#rid114">114</a>]. Nonetheless, lung transplantation presents a unique risk for transmitting respiratory viruses of donor origin, since the lungs are constantly exposed to the environment. At least two confirmed cases of transmission of influenza of donor origin have been reported [<a href="#rid115">115,116</a>]. Because of the risk of transmission, guidelines recommend against the use of donors with recognized influenza infection for lung transplantation [<a href="#rid117">117</a>]. Donors with documented current pneumonia secondary to other CRVs should generally also be excluded from lung donation. Transmission of SARS-CoV-2 through lung transplantation has been documented and testing of the lower airway by PCR is required by Organ Procurement and Transplantation Network policy in the United States [<a href="#rid118">118,119</a>]. Similarly, lung transplantation should generally be delayed in candidates with a documented CRV until they have cleared the virus.</p><p class="headingAnchor" id="H1664679868"><span class="h1">HERPES VIRUSES</span><span class="headingEndMark"> — </span>The herpesviruses (eg, cytomegalovirus [CMV], herpes simplex virus [HSV], varicella-zoster virus [VZV]) are important causes of infection in lung transplant recipients because they commonly reactivate in the setting of immunosuppression when prophylaxis is not used. However, herpesvirus prophylaxis is effective at preventing these infections. Few studies of herpes viruses other than CMV have focused on lung transplant recipients. Treatment and prophylaxis recommendations are derived mostly from data in other transplant populations.</p><p class="headingAnchor" id="H3093491"><span class="h2">Cytomegalovirus</span><span class="headingEndMark"> — </span>CMV, a member of the betaherpesvirus group, is an important cause of morbidity and mortality in lung transplant recipients. CMV infection in the lung transplant recipient may range from asymptomatic viremia (CMV infection) to CMV disease manifested as a viral syndrome or as tissue invasive disease, most commonly pneumonitis. Oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> is used to prevent CMV reactivation in lung transplant recipients who are at risk. The prevention and treatment of CMV in lung transplant recipients are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1664679875"><span class="h2">Herpes simplex virus</span><span class="headingEndMark"> — </span>Prevalence rates of HSV-1 and -2 in adults in the United States are 80 and 26 percent, respectively [<a href="#rid120">120,121</a>]. HSV-seropositive lung transplant recipients are at risk for post-transplant reactivation. Although the classic findings of vesicular lesions in the oral or genital regions occur frequently, atypical presentations may occur, so suspicious lesions should be tested for the presence of HSV by direct florescent antibody testing, culture, or polymerase chain reaction [<a href="#rid122">122</a>]. (See  <a class="medical medical_review" href="/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection"</a> and  <a class="medical medical_review" href="/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection"</a>.)</p><p class="headingAnchor" id="H1931452"><span class="h3">Prophylaxis</span><span class="headingEndMark"> — </span>Prophylaxis for CMV will effectively prevent most cases of HSV reactivation. (See <a class="local">'Cytomegalovirus'</a> above.)</p><p>We give HSV prophylaxis to all lung transplant recipients who are not receiving CMV prophylaxis (ie, patients who are seronegative for CMV and received an allograft from a CMV-seronegative donor) or who are receiving <a class="drug drug_general" data-topicid="115632" href="/d/drug information/115632.html" rel="external">letermovir</a> for CMV prophylaxis. Appropriate regimens for HSV prophylaxis in patients with normal renal function include <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> 400 or 800 mg orally twice daily, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> 500 mg orally twice daily, or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a> 500 mg orally twice daily  (<a class="graphic graphic_table graphicRef78763" href="/d/graphic/78763.html" rel="external">table 4</a>) [<a href="#rid122">122</a>]. We continue prophylaxis for three to six months following transplantation as well as during periods of lymphodepletion for the treatment of rejection.</p><p>The evidence to support prophylaxis to prevent the reactivation of HSV comes from trials and a meta-analysis in solid organ transplant recipients [<a href="#rid123">123-125</a>], a trial and a cohort study in hematopoietic cell transplant recipients [<a href="#rid126">126,127</a>], and a trial in human immunodeficiency virus (HIV)-infected patients [<a href="#rid128">128</a>].</p><p class="headingAnchor" id="H4141360884"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>For patients with mucocutaneous HSV and normal renal function, <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> 400 mg three times daily, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> 1 g orally twice daily, or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a> 500 mg orally twice daily should be initiated promptly and continued until all lesions are fully healed [<a href="#rid122">122</a>]. For severe or visceral disease, intravenous acyclovir should be used [<a href="#rid122">122</a>].</p><p class="headingAnchor" id="H1664679882"><span class="h2">Varicella-zoster virus</span><span class="headingEndMark"> — </span>Over 90 percent of adults have had chickenpox or have been vaccinated [<a href="#rid129">129</a>]. VZV reactivation occurs in approximately 8 to 11 percent of solid transplant recipients during the first four years following transplantation [<a href="#rid122">122</a>].</p><p class="headingAnchor" id="H1967768071"><span class="h3">Pre-exposure prophylaxis</span><span class="headingEndMark"> — </span>CMV prophylaxis with <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> or <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> will effectively prevent most cases of VZV reactivation. (See <a class="local">'Cytomegalovirus'</a> above.)</p><p>We give VZV prophylaxis to all lung transplant recipients who are not receiving CMV prophylaxis (ie, patients who are seronegative for CMV and received an allograft from a CMV-seronegative donor) or who are receiving <a class="drug drug_general" data-topicid="115632" href="/d/drug information/115632.html" rel="external">letermovir</a> prophylaxis for CMV. Appropriate regimens are the same as those used for HSV prophylaxis (<a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>, or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>)  (<a class="graphic graphic_table graphicRef78763" href="/d/graphic/78763.html" rel="external">table 4</a>). Prophylaxis is typically continued for three to six months as well as during periods of lymphodepletion for the treatment of rejection. (See <a class="local">'Prophylaxis'</a> above.)</p><p>The evidence to support prophylaxis to prevent the reactivation of VZV comes from a trial and meta-analysis in solid organ transplant recipients [<a href="#rid123">123,125</a>] and a trial in hematopoietic cell transplant recipients [<a href="#rid126">126</a>].</p><p class="headingAnchor" id="H286631998"><span class="h3">Postexposure prophylaxis</span><span class="headingEndMark"> — </span>If nonimmune transplant recipients are exposed to a patient with documented primary VZV, immunoprophylaxis with VZV-specific <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> if available or intravenous immunoglobulin if VZV-specific immune globulin is not available should be given; addition of pre-emptive antiviral therapy can also be considered [<a href="#rid122">122</a>]. Detailed recommendations are provided separately. (See  <a class="medical medical_review" href="/d/html/8273.html" rel="external">"Post-exposure prophylaxis against varicella-zoster virus infection"</a>.)</p><p>In adult immunocompetent transplant candidates who are seronegative for VZV, two doses of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> should be given four to eight weeks apart; because the vaccine is a live-virus vaccine, patients should not undergo transplantation for at least two weeks, but preferably four weeks, after receipt of the vaccine [<a href="#rid122">122,129</a>]. Some experts recommend waiting at least four weeks after receipt of live vaccines before proceeding to transplantation [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H4133260343"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Patients with primary VZV infection (chickenpox), multidermatomal zoster, and zoster affecting the trigeminal or geniculate ganglion should be treated with intravenous <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>. Patients with localized dermatomal zoster can be treated orally with <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a> as long as close follow-up is assured. Patients with progressive or new lesions despite two to three days of oral therapy should be admitted for intravenous acyclovir therapy. (See  <a class="medical medical_review" href="/d/html/8336.html" rel="external">"Treatment of varicella (chickenpox) infection"</a> and  <a class="medical medical_review" href="/d/html/8293.html" rel="external">"Treatment of herpes zoster", section on 'Immunocompromised patients'</a>.)</p><p class="headingAnchor" id="H3415880436"><span class="h3">Infection control</span><span class="headingEndMark"> — </span>All hospitalized patients with primary VZV or herpes zoster should be placed on airborne and contact precautions; this should be continued until all lesions are crusted, which can be delayed in immunocompromised hosts [<a href="#rid122">122</a>]. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Airborne precautions'</a> and  <a class="medical medical_review" href="/d/html/4047.html" rel="external">"Prevention and control of varicella-zoster virus in hospitals"</a>.)</p><p class="headingAnchor" id="H3108754318"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117424.html" rel="external">"Society guideline links: Infections in solid organ transplant recipients"</a>.)</p><p class="headingAnchor" id="H3092518"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Range of viral infections</strong> – A wide range of viral infections complicate lung transplantation. Important viruses in lung transplant recipients include the community respiratory viruses (CRVs; eg, influenza, respiratory syncytial virus, adenovirus, parainfluenza virus, human metapneumovirus, rhinovirus), cytomegalovirus (CMV), herpes simplex virus (HSV), and varicella-zoster virus (VZV). CMV infection in lung transplant recipients and SARS-CoV-2 infection is covered in detail separately. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory tract infection and disseminated disease</strong> – Because of the lung's exposure to the environment, inhaled viruses are of concern and can be divided into pathogens that primarily affect the respiratory tract (CRVs, such as influenza, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, and rhinovirus) and those that predominantly affect other tissues (eg, CMV, VZV, HSV, measles); adenovirus can be either a primary respiratory pathogen or the lungs may be involved as part of a disseminated infection. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seasonal pattern for CRVs</strong> – The seasonal patterns of the individual CRVs in lung transplant recipients are similar to those seen in immunocompetent hosts. As an example, outbreaks of influenza generally occur during the winter months in the northern and southern hemispheres (which occur at different times of the year). In the temperate northern hemisphere, influenza predominates from November through April and typically <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fabout%2Fseason%2Findex.html%23%3A%7E%3Atext%3DThe%2520exact%2520timing%2520and%2520duration%2Clast%2520as%2520late%2520as%2520Mayin&amp;token=pjvTpcSx2KTfZ9EIIsUgEsgJ5xRNzSopOb9XLCs3zBUq6hLg4r8AFa8NS%2BpJBhaQsIWs%2BJC7QjFAipVt0jj1uYR4UA0KAUCg27iEQxYO3Lcn6kVhOx4XgKQRsGc6W5HMbK9lV4zUGVy5EtfgvqQmhw%3D%3D&amp;TOPIC_ID=13952" target="_blank">peaks</a> in February. In tropical regions, influenza occurs throughout the year. (See <a class="local">'Seasonal patterns'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRV symptoms are nonspecific</strong> – CRVs can cause both upper and lower respiratory tract infections in lung transplant recipients. There are no pathognomonic signs or symptoms associated with a single CRV, and there is almost always cocirculation of multiple viral pathogens. It is therefore impossible to make a virologic diagnosis clinically, and respiratory samples must be tested to make a definitive virologic diagnosis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRV association with rejection</strong> – CRVs, particularly when associated with lower respiratory tract involvement, may be associated with rejection, particularly chronic lung allograft dysfunction. The association between CRVs and acute rejection has not been established, with studies showing conflicting results. (See <a class="local">'Rejection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing required for CRV diagnosis</strong> – CRVs should be considered and tested for in any lung transplant recipient presenting with fever and respiratory symptoms and/or changes in pulmonary function testing results. In lung transplant recipients with mild to moderate respiratory illness, we start by obtaining nasopharyngeal samples (swabs or washings) for CRVs. We favor molecular diagnostic techniques (eg, the polymerase chain reaction) and typically test for SARS-CoV-2, influenza, parainfluenza virus, RSV, adenovirus, and human metapneumovirus. We have a low threshold for repeating testing for certain CRVs (eg, influenza) if initial testing is negative but the virus is known to be circulating locally; this is particularly important if effective antiviral therapy is available. (See <a class="local">'Approach to diagnosis'</a> above and <a class="local">'Diagnostic tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of bronchoscopy</strong> – In patients who have evidence of pneumonia and who are severely ill and in whom the diagnosis has not been made by less invasive techniques, we generally favor bronchoscopy with bronchoalveolar lavage (BAL). The following table lists various tests that can be performed on BAL fluid  (<a class="graphic graphic_table graphicRef70685" href="/d/graphic/70685.html" rel="external">table 2</a>). The decision of which studies to send depends upon the individual patient's epidemiologic exposures and clinical findings and on availability at specific hospital laboratories. When the diagnosis is not established by studies of BAL fluid or noninvasive testing, histopathology of lung tissue can be helpful. (See <a class="local">'Approach to diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRV management</strong> – The management of CRVs varies with the specific virus causing the infection. Effective antiviral agents are available for certain CRVs (eg, influenza, SARS-CoV-2) but not for others. (See <a class="local">'Management'</a> above and <a class="local">'Therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When treating influenza, we typically use a neuraminidase inhibitor (eg, <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a>) but antiviral selection should be guided by the recommendations of local and national health agencies because of the potential for resistance in circulating strains. We continue antiviral therapy in lung transplant recipients with influenza until shedding is no longer detected by the real-time reverse-transcriptase polymerase chain reaction; this will typically require more than the five days of therapy recommended for immunocompetent individuals. The management of other CRVs is discussed above. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The management of COVID-19 in lung transplant recipients is similar to the general population, although the threshold to treat with monoclonal antibodies is lower than in nonimmunocompromised patients  (<a class="graphic graphic_algorithm graphicRef134578" href="/d/graphic/134578.html" rel="external">algorithm 1</a>). Similarly, the threshold to use investigational therapies may also be lower but practice varies among transplant centers. (See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'COVID-19-specific therapy'</a> and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRV vaccination</strong> – Among the CRVs, a vaccine is available for influenza virus and SARS-CoV-2. Annual influenza vaccination should be given to all lung transplant recipients (after the early post-transplant period) and their close contacts. An <a class="drug drug_general" data-topicid="9055" href="/d/drug information/9055.html" rel="external">inactivated influenza vaccine</a> should be used in lung transplant recipients; the live attenuated intranasal vaccine is contraindicated. (See <a class="local">'Vaccination'</a> above and  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRV pre-exposure prophylaxis</strong> – For lung transplant recipients in whom influenza vaccination is contraindicated or for those who are likely to have an inadequate response to the vaccine (eg, those receiving therapy for acute rejection or who underwent transplantation recently), we suggest pre-exposure antiviral prophylaxis for 12 weeks starting at the beginning of influenza season  (<a class="graphic graphic_table graphicRef50350" href="/d/graphic/50350.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We are most likely to give pre-exposure prophylaxis to those who underwent transplantation within the past month. In patients who meet criteria for pre-exposure prophylaxis but who are not receiving it, we give postexposure prophylaxis following exposure to a patient with influenza. (See <a class="local">'Prevention'</a> above and  <a class="medical medical_review" href="/d/html/7017.html" rel="external">"Seasonal influenza in adults: Role of antiviral prophylaxis for prevention", section on 'Postexposure antiviral prophylaxis'</a>.)</p><p></p><p class="bulletIndent1">Lung transplant recipients are also eligible for pre-exposure prophylaxis with <a class="drug drug_general" data-topicid="134627" href="/d/drug information/134627.html" rel="external">tixagevimab-cilgavimab</a> in the United States. Although availability is limited, we generally try to obtain pre-exposure prophylaxis for lung transplant recipients when COVID-19 prevalence is high because of their high-risk status. (See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Monoclonal antibodies ineffective for pre-exposure prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes viruses</strong> – The herpesviruses (eg, CMV, HSV, VZV) are important causes of infection in lung transplant recipients because they commonly reactivate in the setting of immunosuppression when prophylaxis is not used. Specific herpesvirus prophylaxis is effective at preventing these infections. (See <a class="local">'Herpes viruses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of CMV reactivation</strong> – Oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> is used to prevent CMV reactivation in lung transplant recipients who are at risk. The prevention and treatment of CMV in lung transplant recipients are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HSV and VZV prophylaxis</strong> – We recommend prophylaxis against HSV and VZV for all solid organ transplant recipients who are not receiving CMV prophylaxis (ie, patients who are seronegative for CMV and received an allograft from a CMV-seronegative donor) or who are receiving <a class="drug drug_general" data-topicid="115632" href="/d/drug information/115632.html" rel="external">letermovir</a> for CMV prophylaxis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Appropriate regimens for HSV and VZV prophylaxis in patients with normal renal function include <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> 400 to 800 mg orally twice daily, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> 500 mg orally twice daily, or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a> 500 mg orally twice daily. We continue prophylaxis for three to six months following transplantation as well as during periods of lymphodepletion for the treatment of rejection. (See <a class="local">'Prophylaxis'</a> above.)</p><p></p><p class="headingAnchor" id="H900799185"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic do not necessarily represent the views of the National Institutes of Health or the United States Government.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Garbino J, Soccal PM, Aubert JD, et al. Respiratory viruses in bronchoalveolar lavage: a hospital-based cohort study in adults. Thorax 2009; 64:399.</a></li><li><a class="nounderline abstract_t">Milstone AP, Brumble LM, Barnes J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006; 28:131.</a></li><li><a class="nounderline abstract_t">Gerna G, Vitulo P, Rovida F, et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006; 78:408.</a></li><li><a class="nounderline abstract_t">Rovida F, Percivalle E, Zavattoni M, et al. Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. J Med Virol 2005; 75:336.</a></li><li><a class="nounderline abstract_t">Weinberg A, Zamora MR, Li S, et al. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. J Clin Virol 2002; 25:171.</a></li><li><a class="nounderline abstract_t">Gottlieb J, Schulz TF, Welte T, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009; 87:1530.</a></li><li><a class="nounderline abstract_t">Weinberg A, Lyu DM, Li S, et al. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis 2010; 12:330.</a></li><li><a class="nounderline abstract_t">Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89:1028.</a></li><li><a class="nounderline abstract_t">Astegiano S, Bergallo M, Solidoro P, et al. Prevalence and clinical impact of polyomaviruses KI and WU in lung transplant recipients. Transplant Proc 2010; 42:1275.</a></li><li><a class="nounderline abstract_t">Fox BD, Raviv Y, Rozengarten D, et al. Pandemic influenza (H1N1): impact on lung transplant recipients and candidates. J Heart Lung Transplant 2010; 29:1034.</a></li><li><a class="nounderline abstract_t">Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther 2007; 12:627.</a></li><li><a class="nounderline abstract_t">Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5:2031.</a></li><li><a class="nounderline abstract_t">Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007; 110:1681.</a></li><li><a class="nounderline abstract_t">Costa C, Bergallo M, Astegiano S, et al. Detection of human rhinoviruses in the lower respiratory tract of lung transplant recipients. Arch Virol 2011; 156:1439.</a></li><li><a class="nounderline abstract_t">Gerna G, Piralla A, Rovida F, et al. Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients. J Med Virol 2009; 81:1498.</a></li><li><a class="nounderline abstract_t">Ambrosioni J, Bridevaux PO, Aubert JD, et al. Role of rhinovirus load in the upper respiratory tract and severity of symptoms in lung transplant recipients. J Clin Virol 2015; 64:1.</a></li><li><a class="nounderline abstract_t">Bridevaux PO, Aubert JD, Soccal PM, et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax 2014; 69:32.</a></li><li><a class="nounderline abstract_t">Franquet T. Imaging of pulmonary viral pneumonia. Radiology 2011; 260:18.</a></li><li><a class="nounderline abstract_t">Apostolopoulou A, Clancy CJ, Skeel A, Nguyen MH. Invasive Pulmonary Aspergillosis Complicating Noninfluenza Respiratory Viral Infections in Solid Organ Transplant Recipients. Open Forum Infect Dis 2021; 8:ofab478.</a></li><li><a class="nounderline abstract_t">Permpalung N, Liang T, Gopinath S, et al. Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year. J Heart Lung Transplant 2023; 42:953.</a></li><li><a class="nounderline abstract_t">Kaiser L, Aubert JD, Pache JC, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 2006; 174:1392.</a></li><li><a class="nounderline abstract_t">Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21:559.</a></li><li><a class="nounderline abstract_t">Chakinala MM, Walter MJ. Community acquired respiratory viral infections after lung transplantation: clinical features and long-term consequences. Semin Thorac Cardiovasc Surg 2004; 16:342.</a></li><li><a class="nounderline abstract_t">Garantziotis S, Howell DN, McAdams HP, et al. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 2001; 119:1277.</a></li><li><a class="nounderline abstract_t">Garbino J, Gerbase MW, Wunderli W, et al. Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact. Am J Respir Crit Care Med 2004; 170:1197.</a></li><li><a class="nounderline abstract_t">Husain S, Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect 2002; 17:310.</a></li><li><a class="nounderline abstract_t">Palmer SM Jr, Henshaw NG, Howell DN, et al. Community respiratory viral infection in adult lung transplant recipients. Chest 1998; 113:944.</a></li><li><a class="nounderline abstract_t">Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection - myth or reality? Am J Transplant 2003; 3:245.</a></li><li><a class="nounderline abstract_t">Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170:181.</a></li><li><a class="nounderline abstract_t">Manuel O, Estabrook M, AST Infectious Diseases Community of Practice. RNA respiratory viruses in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:212.</a></li><li><a class="nounderline abstract_t">Fisher CE, Preiksaitis CM, Lease ED, et al. Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. Clin Infect Dis 2016; 62:313.</a></li><li><a class="nounderline abstract_t">Allyn PR, Duffy EL, Humphries RM, et al. Graft Loss and CLAD-Onset Is Hastened by Viral Pneumonia After Lung Transplantation. Transplantation 2016; 100:2424.</a></li><li><a class="nounderline abstract_t">Peghin M, Los-Arcos I, Hirsch HH, et al. Community-acquired Respiratory Viruses Are a Risk Factor for Chronic Lung Allograft Dysfunction. Clin Infect Dis 2019; 69:1192.</a></li><li><a class="nounderline abstract_t">de Zwart AES, Riezebos-Brilman A, Alffenaar JC, et al. Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients. Am J Transplant 2020; 20:3529.</a></li><li><a class="nounderline abstract_t">Winter JB, Gouw AS, Groen M, et al. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation 1994; 57:418.</a></li><li><a class="nounderline abstract_t">Magnusson J, Westin J, Andersson LM, et al. Viral Respiratory Tract Infection During the First Postoperative Year Is a Risk Factor for Chronic Rejection After Lung Transplantation. Transplant Direct 2018; 4:e370.</a></li><li><a class="nounderline abstract_t">de Zwart A, Riezebos-Brilman A, Lunter G, et al. Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies. Clin Infect Dis 2022; 74:2252.</a></li><li><a class="nounderline abstract_t">Bailey ES, Zemke JN, Choi JY, Gray GC. A Mini-Review of Adverse Lung Transplant Outcomes Associated With Respiratory Viruses. Front Immunol 2019; 10:2861.</a></li><li><a class="nounderline abstract_t">Soccal PM, Aubert JD, Bridevaux PO, et al. Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients. Clin Infect Dis 2010; 51:163.</a></li><li><a class="nounderline abstract_t">Vu DL, Bridevaux PO, Aubert JD, et al. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11:1071.</a></li><li><a class="nounderline abstract_t">Neurohr C, Huppmann P, Leuchte H, et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005; 5:2982.</a></li><li><a class="nounderline abstract_t">Manuel O, Kumar D, Moussa G, et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009; 87:719.</a></li><li><a class="nounderline abstract_t">Engelmann I, Welte T, Fühner T, et al. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol 2009; 45:47.</a></li><li><a class="nounderline abstract_t">Sumino KC, Agapov E, Pierce RA, et al. Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment. J Infect Dis 2005; 192:1052.</a></li><li><a class="nounderline abstract_t">Hopkins PM, Plit ML, Carter IW, et al. Indirect fluorescent antibody testing of nasopharyngeal swabs for influenza diagnosis in lung transplant recipients. J Heart Lung Transplant 2003; 22:161.</a></li><li><a class="nounderline abstract_t">Englund JA, Piedra PA, Jewell A, et al. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol 1996; 34:1649.</a></li><li><a class="nounderline abstract_t">Lieberman D, Lieberman D, Shimoni A, et al. Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling. J Clin Microbiol 2009; 47:3439.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Guidance for clinicians on the use of rapid influenza diagnostic tests. http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm (Accessed on April 04, 2012).</li><li><a class="nounderline abstract_t">Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis 2019; 68:895.</a></li><li><a class="nounderline abstract_t">Ison MG. Antiviral therapies for respiratory viral infections in lung transplant patients. Antivir Ther 2012; 17:193.</a></li><li><a class="nounderline abstract_t">Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.</a></li><li><a class="nounderline abstract_t">Ison MG. Anti-influenza therapy: The emerging challenge of resistance. Therapy 2009; 6:883.</a></li><li><a class="nounderline abstract_t">Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018; 379:913.</a></li><li><a class="nounderline abstract_t">Uehara T, Hayden FG, Kawaguchi K, et al. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. J Infect Dis 2020; 221:346.</a></li><li><a class="nounderline abstract_t">Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521.</a></li><li><a class="nounderline abstract_t">Ison MG, Sharma A, Shepard JA, et al. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant 2008; 27:282.</a></li><li><a class="nounderline abstract_t">Mitha E, Krivan G, Jacobs F, et al. Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients. Infect Dis Ther 2019; 8:613.</a></li><li><a class="nounderline abstract_t">Natori Y, Shiotsuka M, Slomovic J, et al. A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. Clin Infect Dis 2018; 66:1698.</a></li><li><a class="nounderline abstract_t">Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 2019; 33:e13563.</a></li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a class="nounderline abstract_t">Mossad SB. Larger dose of intradermal influenza vaccination may be more immunogenic in transplant recipients. Am J Transplant 2008; 8:1073; author reply 1074.</a></li><li><a class="nounderline abstract_t">Manuel O, Humar A, Chen MH, et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant 2007; 7:2567.</a></li><li><a class="nounderline abstract_t">Hayney MS, Welter DL, Francois M, et al. Influenza vaccine antibody responses in lung transplant recipients. Prog Transplant 2004; 14:346.</a></li><li><a class="nounderline abstract_t">Mazzone PJ, Mossad SB, Mawhorter SD, et al. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 2001; 18:971.</a></li><li><a class="nounderline abstract_t">Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9:493.</a></li><li><a class="nounderline abstract_t">Schuurmans MM, Tini GM, Dalar L, et al. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J Heart Lung Transplant 2011; 30:685.</a></li><li><a class="nounderline abstract_t">Chong PP, Handler L, Weber DJ. A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients. Clin Infect Dis 2018; 66:1802.</a></li><li><a class="nounderline abstract_t">Haddadin Z, Krueger K, Thomas LD, et al. Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients. Am J Transplant 2021; 21:938.</a></li><li><a class="nounderline abstract_t">Ison MG, Szakaly P, Shapira MY, et al. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther 2012; 17:955.</a></li><li><a class="nounderline abstract_t">Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 2010; 12:38.</a></li><li><a class="nounderline abstract_t">Weigt SS, Gregson AL, Deng JC, et al. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med 2011; 32:471.</a></li><li><a class="nounderline abstract_t">Burrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency. J Heart Lung Transplant 2015; 34:958.</a></li><li><a class="nounderline abstract_t">Marcelin JR, Wilson JW, Razonable RR, Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 2014; 16:242.</a></li><li><a class="nounderline abstract_t">Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 2016; 18:210.</a></li><li><a class="nounderline abstract_t">Chemaly RF, Aitken SL, Wolfe CR, et al. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis 2016; 18:634.</a></li><li><a class="nounderline abstract_t">Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009; 28:67.</a></li><li><a class="nounderline abstract_t">Trang TP, Whalen M, Hilts-Horeczko A, et al. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature. Transpl Infect Dis 2018; 20:e12844.</a></li><li><a class="nounderline abstract_t">Mueller SW, Kiser TH, Morrisette T, et al. Ribavirin and cellular ribavirin-triphosphate concentrations in blood and bronchoalveolar lavage fluid in two lung transplant patients with respiratory syncytial virus. Transpl Infect Dis 2021; 23:e13464.</a></li><li><a class="nounderline abstract_t">Murris-Espin M, Didier A, Carre P, et al. Continuous aerosolised tribavirin for respiratory syncytial virus infection in lung transplant recipients. Lancet 1993; 341:897.</a></li><li><a class="nounderline abstract_t">McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant 2003; 22:745.</a></li><li><a class="nounderline abstract_t">Flynn JD, Akers WS, Jones M, et al. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature. Pharmacotherapy 2004; 24:932.</a></li><li><a class="nounderline abstract_t">Blanco JC, Boukhvalova MS, Hemming P, et al. Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection. Expert Rev Anti Infect Ther 2005; 3:945.</a></li><li><a class="nounderline abstract_t">Uçkay I, Gasche-Soccal PM, Kaiser L, et al. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy. J Heart Lung Transplant 2010; 29:299.</a></li><li><a class="nounderline abstract_t">Li L, Avery R, Budev M, et al. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2012; 31:839.</a></li><li><a class="nounderline abstract_t">Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005; 24:2114.</a></li><li><a class="nounderline abstract_t">Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117:2755.</a></li><li><a class="nounderline abstract_t">Falsey AR, Koval C, DeVincenzo JP, Walsh EE. Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons. Transpl Infect Dis 2017; 19.</a></li><li><a class="nounderline abstract_t">Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183:531.</a></li><li><a class="nounderline abstract_t">Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant 2016; 35:213.</a></li><li><a class="nounderline abstract_t">Beigel JH, Nam HH, Adams PL, et al. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res 2019; 167:45.</a></li><li class="breakAll">FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine (Accessed on June 09, 2023).</li><li><a class="nounderline abstract_t">Papi A, Ison MG, Langley JM, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med 2023; 388:595.</a></li><li><a class="nounderline abstract_t">Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med 2023; 388:1465.</a></li><li><a class="nounderline abstract_t">Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med 2022; 386:837.</a></li><li><a class="nounderline abstract_t">Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98:573.</a></li><li><a class="nounderline abstract_t">Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35:S65.</a></li><li><a class="nounderline abstract_t">Ohori NP, Michaels MG, Jaffe R, et al. Adenovirus pneumonia in lung transplant recipients. Hum Pathol 1995; 26:1073.</a></li><li><a class="nounderline abstract_t">Grimley MS, Chemaly RF, Englund JA, et al. Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. Biol Blood Marrow Transplant 2017; 23:512.</a></li><li class="breakAll">ClinicalTrials.gov. Expanded access protocol to provide brincidofovir for the treatment of serious adenovirus infection or disease. https://clinicaltrials.gov/ct2/show/NCT02596997 (Accessed on April 26, 2018).</li><li><a class="nounderline abstract_t">Doan ML, Mallory GB, Kaplan SL, et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant 2007; 26:883.</a></li><li><a class="nounderline abstract_t">Raza K, Ismailjee SB, Crespo M, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007; 26:862.</a></li><li><a class="nounderline abstract_t">Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008; 178:876.</a></li><li><a class="nounderline abstract_t">Bergallo M, Costa C, Terlizzi ME, et al. Quantitative detection of the new polyomaviruses KI, WU and Merkel cell virus in transbronchial biopsies from lung transplant recipients. J Clin Pathol 2010; 63:722.</a></li><li><a class="nounderline abstract_t">Garbino J, Crespo S, Aubert JD, et al. A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)-related human coronavirus infection. Clin Infect Dis 2006; 43:1009.</a></li><li><a class="nounderline abstract_t">Garbino J, Gerbase MW, Wunderli W, et al. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest 2004; 125:1033.</a></li><li><a class="nounderline abstract_t">Shalhoub S, Husain S. Community-acquired respiratory viral infections in lung transplant recipients. Curr Opin Infect Dis 2013; 26:302.</a></li><li><a class="nounderline abstract_t">Siebrasse EA, Pastrana DV, Nguyen NL, et al. WU polyomavirus in respiratory epithelial cells from lung transplant patient with Job syndrome. Emerg Infect Dis 2015; 21:103.</a></li><li><a class="nounderline abstract_t">Danziger-Isakov L, Steinbach WJ, Paulsen G, et al. A Multicenter Consortium to Define the Epidemiology and Outcomes of Pediatric Solid Organ Transplant Recipients With Inpatient Respiratory Virus Infection. J Pediatric Infect Dis Soc 2019; 8:197.</a></li><li><a class="nounderline abstract_t">Kumar D, Tellier R, Draker R, et al. Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant 2003; 3:977.</a></li><li><a class="nounderline abstract_t">AlGhamdi M, Mushtaq F, Awn N, Shalhoub S. MERS CoV infection in two renal transplant recipients: case report. Am J Transplant 2015; 15:1101.</a></li><li><a class="nounderline abstract_t">Heldman MR, Kates OS, Safa K, et al. COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study. Am J Transplant 2021; 21:2774.</a></li><li><a class="nounderline abstract_t">Okumura K, Jyothula S, Kaleekal T, Dhand A. 1-Year Outcomes of Lung Transplantation for Coronavirus Disease 2019-Associated End-Stage Lung Disease in the United States. Clin Infect Dis 2023; 76:2140.</a></li><li><a class="nounderline abstract_t">Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9:1929.</a></li><li><a class="nounderline abstract_t">Le Page AK, Kainer G, Glanville AR, et al. Influenza B virus transmission in recipients of kidney and lung transplants from an infected donor. Transplantation 2010; 90:99.</a></li><li><a class="nounderline abstract_t">Meylan PR, Aubert JD, Kaiser L. Influenza transmission to recipient through lung transplantation. Transpl Infect Dis 2007; 9:55.</a></li><li><a class="nounderline abstract_t">Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10:18.</a></li><li><a class="nounderline abstract_t">Kaul DR, Valesano AL, Petrie JG, et al. Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing. Am J Transplant 2021; 21:2885.</a></li><li class="breakAll">Organ Procurement and Transplantation Network. Summary of Current Evidence and Information– Donor SARS-CoV-2 Testing &amp; Organ Recovery from Donors with a History of COVID-19. https://optn.transplant.hrsa.gov/media/kkhnlwah/sars-cov-2-summary-of-evidence.pdf (Accessed on January 24, 2022).</li><li><a class="nounderline abstract_t">Schillinger JA, Xu F, Sternberg MR, et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis 2004; 31:753.</a></li><li><a class="nounderline abstract_t">Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964.</a></li><li><a class="nounderline abstract_t">Pergam SA, Limaye AP, AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13622.</a></li><li><a class="nounderline abstract_t">Pettersson E, Hovi T, Ahonen J, et al. Prophylactic oral acyclovir after renal transplantation. Transplantation 1985; 39:279.</a></li><li><a class="nounderline abstract_t">Seale L, Jones CJ, Kathpalia S, et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 1985; 254:3435.</a></li><li><a class="nounderline abstract_t">Fiddian P, Sabin CA, Griffiths PD. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis 2002; 186 Suppl 1:S110.</a></li><li><a class="nounderline abstract_t">Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. Blood 2006; 107:1800.</a></li><li><a class="nounderline abstract_t">Erard V, Wald A, Corey L, et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196:266.</a></li><li><a class="nounderline abstract_t">Conant MA, Schacker TW, Murphy RL, et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002; 13:12.</a></li><li><a class="nounderline abstract_t">Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.</a></li></ol></div><div id="topicVersionRevision">Topic 13952 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19174425" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Respiratory viruses in bronchoalveolar lavage: a hospital-based cohort study in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510454" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A single-season prospective study of respiratory viral infections in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16419110" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602736" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12367651" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19461490" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456714" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20075787" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20534279" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence and clinical impact of polyomaviruses KI and WU in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558087" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pandemic influenza (H1N1): impact on lung transplant recipients and candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17944270" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Respiratory viral infections in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996256" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502457" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21461933" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Detection of human rhinoviruses in the lower respiratory tract of lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19551831" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25728070" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Role of rhinovirus load in the upper respiratory tract and severity of symptoms in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24025442" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21697307" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Imaging of pulmonary viral pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34805426" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Invasive Pulmonary Aspergillosis Complicating Noninfluenza Respiratory Viral Infections in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36925381" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008640" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chronic rhinoviral infection in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11983546" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Respiratory viruses and chronic rejection in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15635538" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Community acquired respiratory viral infections after lung transplantation: clinical features and long-term consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11296201" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15361367" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12497548" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554629" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Community respiratory viral infection in adult lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614277" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection - myth or reality?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15130908" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465014" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : RNA respiratory viruses in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26565010" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467538" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Graft Loss and CLAD-Onset Is Hastened by Viral Pneumonia After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30561555" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Community-acquired Respiratory Viruses Are a Risk Factor for Chronic Lung Allograft Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32449200" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8108878" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30255130" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Viral Respiratory Tract Infection During the First Postoperative Year Is a Risk Factor for Chronic Rejection After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35022697" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31921130" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A Mini-Review of Adverse Lung Transplant Outcomes Associated With Respiratory Viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20524853" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521473" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303014" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19295317" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19303808" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16107959" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12581764" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Indirect fluorescent antibody testing of nasopharyngeal swabs for influenza diagnosis in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8784563" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19726607" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19726607" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30834445" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22311542" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antiviral therapies for respiratory viral infections in lung transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21248682" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anti-influenza therapy: The emerging challenge of resistance</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30184455" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31309975" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620116" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342750" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Outcome of influenza infection managed with oseltamivir in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31667696" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29253089" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34448800" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31002409" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18318782" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Larger dose of intradermal influenza vaccination may be more immunogenic in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908277" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15663020" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Influenza vaccine antibody responses in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11829104" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The humoral immune response to influenza vaccination in lung transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628174" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444211" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29253095" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32885604" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22728756" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19761558" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21858751" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25753833" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24621016" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26923867" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27214684" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Aerosolized ribavirin: the most expensive drug for pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19134533" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29360277" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32920958" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Ribavirin and cellular ribavirin-triphosphate concentrations in blood and bronchoalveolar lavage fluid in two lung transplant patients with respiratory syncytial virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8096599" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Continuous aerosolised tribavirin for respiratory syncytial virus infection in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873542" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15303457" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16307507" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837611" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22621746" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364859" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21139081" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Management of RSV infections in adult recipients of hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28054734" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20851929" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26452996" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30974127" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30974127" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36791160" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37018468" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35235726" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11468152" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068815" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7557939" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Adenovirus pneumonia in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28063938" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28063938" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845926" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17692793" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18658110" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595181" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Quantitative detection of the new polyomaviruses KI, WU and Merkel cell virus in transbronchial biopsies from lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16983613" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)-related human coronavirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006965" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Respiratory viruses and severe lower respiratory tract complications in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806892" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Community-acquired respiratory viral infections in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25531075" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : WU polyomavirus in respiratory epithelial cells from lung transplant patient with Job syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29538674" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A Multicenter Consortium to Define the Epidemiology and Outcomes of Pediatric Solid Organ Transplant Recipients With Inpatient Respiratory Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859532" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25716741" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : MERS CoV infection in two renal transplant recipients: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34008917" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36757715" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : 1-Year Outcomes of Lung Transplantation for Coronavirus Disease 2019-Associated End-Stage Lung Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19538493" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20606569" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Influenza B virus transmission in recipients of kidney and lung transplants from an infected donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17313474" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Influenza transmission to recipient through lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958321" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Guidance on novel influenza A/H1N1 in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33565705" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33565705" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15608591" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926356" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162727" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2983461" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Prophylactic oral acyclovir after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2999455" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353195" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282339" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17570114" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11802924" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17585291" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
